Annie de Groot, CEO and CSO of the biotech and immunology company EpiVax in Providence. At right is William Martin, CIO and COO.
PBN PHOTO/MICHAEL SALERNO
EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology.
EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. EpiVax Oncology’s goal is to become the leading Neo-epitope based personalized cancer vaccine company, with the ultimate purpose to address major unmet medical needs inadequately addressed by other oncology and immune-oncology treatment approaches. EpiVax Oncology’s ambition is to become a premier cancer precision medicine company, leveraging EpiVax’s world class excellence in computational-immunology, genomics and vaccine design.
Click here to read the full Providence Business News article.
Successful growth continues. Dr. Annie de Groot, CEO and CSO of the biotech and immunology company EpiVax in Providence, meeting with some members of her team. In foreground from left, Steven Vessella and Katie Porter, business development associates.
PBN PHOTO/MICHAEL SALERNO